Chun-Yen Tsao
Overview
Explore the profile of Chun-Yen Tsao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsao C, Sabbatino F, Cheung N, Hsu J, Villani V, Wang X, et al.
Oncoimmunology
. 2015 Sep;
4(8):e1023975.
PMID: 26405581
The beneficial clinical effects of immunotherapy with GD2-specific monoclonal antibodies (mAbs) in melanoma and neuroblastoma patients have stimulated interest in characterizing the mechanisms underlying their antitumor effects. Previous studies have...
2.
Liao H, Tsao C, Alam S, Muldoon M, Vandergrift N, Ma B, et al.
J Virol
. 2013 Feb;
87(8):4185-201.
PMID: 23365441
Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of appropriate envelope (Env) immunogens. Twenty HIV-1 Env glycoproteins were examined for their ability to bind human anti-HIV-1 monoclonal antibodies...
3.
Liao H, Bonsignori M, Alam S, McLellan J, Tomaras G, Moody M, et al.
Immunity
. 2013 Jan;
38(1):176-86.
PMID: 23313589
The RV144 HIV-1 trial of the canary pox vector (ALVAC-HIV) plus the gp120 AIDSVAX B/E vaccine demonstrated an estimated efficacy of 31%, which correlated directly with antibodies to HIV-1 envelope...
4.
Alam S, Liao H, Tomaras G, Bonsignori M, Tsao C, Hwang K, et al.
J Virol
. 2012 Nov;
87(3):1554-68.
PMID: 23175357
An immune correlates analysis of the RV144 HIV-1 vaccine trial revealed that antibody responses to the gp120 V1/V2 region correlated inversely with infection risk. The RV144 protein immunogens (A244-rp120 and...
5.
Bonsignori M, Pollara J, Moody M, Alpert M, Chen X, Hwang K, et al.
J Virol
. 2012 Aug;
86(21):11521-32.
PMID: 22896626
The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the combination of low plasma anti-HIV-1 Env IgA antibodies and high levels...
6.
Bar K, Tsao C, Iyer S, Decker J, Yang Y, Bonsignori M, et al.
PLoS Pathog
. 2012 Jun;
8(5):e1002721.
PMID: 22693447
Single genome sequencing of early HIV-1 genomes provides a sensitive, dynamic assessment of virus evolution and insight into the earliest anti-viral immune responses in vivo. By using this approach, together...
7.
Bonsignori M, Montefiori D, Wu X, Chen X, Hwang K, Tsao C, et al.
J Virol
. 2012 Feb;
86(8):4688-92.
PMID: 22301150
Plasma from a small subset of subjects chronically infected with HIV-1 shows remarkable magnitude and breadth of neutralizing activity. From one of these individuals (CH0219), we isolated two broadly neutralizing...
8.
Bonsignori M, Hwang K, Chen X, Tsao C, Morris L, Gray E, et al.
J Virol
. 2011 Jul;
85(19):9998-10009.
PMID: 21795340
V2/V3 conformational epitope antibodies that broadly neutralize HIV-1 (PG9 and PG16) have been recently described. Since an elicitation of previously known broadly neutralizing antibodies has proven elusive, the induction of...
9.
Santra S, Liao H, Zhang R, Muldoon M, Watson S, Fischer W, et al.
Nat Med
. 2010 Feb;
16(3):324-8.
PMID: 20173754
An effective HIV vaccine must elicit immune responses that recognize genetically diverse viruses. It must generate CD8+ T lymphocytes that control HIV replication and CD4+ T lymphocytes that provide help...
10.
Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, et al.
Cancer Immunol Immunother
. 2007 Dec;
57(7):1079-89.
PMID: 18157673
Introduction: Because of its restricted distribution in normal tissues and its high expression on tumors of neuroectodermal origin, GD2 ganglioside is an excellent target for active specific immunotherapy. However, GD2...